Patents Assigned to Faller & Williams Technology, LLC
  • PKC delta inhibitors for use as therapeutics
    Patent number: 9844534
    Abstract: The invention is directed to compounds that are specific inhibitors of PKC delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers. Neuroendocrine tumor cell lines of pulmonary and gastrointestinal origin are surprisingly sensitive to PKC delta inhibition by the compounds of the invention. The invention is further directed to methods, compositions and kits containing compounds of the formulas (Ia), (IIa), (IIIa), (IVa), and (V) as disclosed and described in FIGS. 11 and 12.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: December 19, 2017
    Assignee: Faller & Williams Technology, LLC
    Inventors: Douglas V. Faller, Robert M. Williams
  • PKC Delta Inhibitors for use as Therapeutics
    Publication number: 20170252322
    Abstract: The invention is directed to compounds that are specific inhibitors of PKC delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers. Neuroendocrine tumor cell lines of pulmonary and gastrointestinal origin are surprisingly sensitive to PKC delta inhibition by the compounds of the invention. The invention is further directed to methods, compositions and kits containing compounds of the formulas (Ia), (IIa), (IIIa), (IVa), and (V) as disclosed and described in FIGS. 11 and 12.
    Type: Application
    Filed: February 6, 2017
    Publication date: September 7, 2017
    Applicant: Faller & Williams Technology, LLC
    Inventors: Douglas V. Faller, Robert M. Williams
  • PKC delta inhibitors for use as therapeutics
    Patent number: 9572793
    Abstract: The invention is directed to compounds that are specific inhibitors of PKC delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers. Neuroendocrine tumor cell lines of pulmonary and gastrointestinal origin are surprisingly sensitive to PKC delta inhibition by the compounds of the invention. The invention is further directed to methods, compositions and kits containing compounds of the formulas (Ia), (IIa), (IIIa), (IVa), and (V) as disclosed and described in FIGS. 11 and 12.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: February 21, 2017
    Assignee: Faller & Williams Technology, LLC
    Inventors: Douglas V. Faller, Robert M. Williams